acalabrutinib CLL
Selected indexed studies
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. (Blood, 2025) [PMID:40198878]
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (N Engl J Med, 2025) [PMID:39976417]
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. (J Clin Oncol, 2021) [PMID:34310172]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (2025) pubmed
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. (2021) pubmed
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. (2025) pubmed
- Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. (2023) pubmed
- Acalabrutinib to assail CLL in the frail. (2025) pubmed
- Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials. (2024) pubmed
- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial. (2025) pubmed
- Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC). (2025) pubmed
- Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial. (2024) pubmed
- Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. (2025) pubmed